NCT00526838View on ClinicalTrials.gov

Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
CancerLymphoma
Interventions
DRUG

XL228

1-hour IV infusion

Trial Locations (4)

27710

Duke University Medical Center, Durham

30322

Winship Cancer Institute of Emory University, Atlanta

48109

University of Michigan Health System, Ann Arbor

90095

UCLA Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Lead Sponsor

Exelixis
All Listed Sponsors
lead

Exelixis

INDUSTRY

NCT00526838 - Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies | Biotech Hunter | Biotech Hunter